Generic Name |
Atezolizumab | |
---|---|---|
IND |
MPDL3280A | |
Brand Name (US) |
||
Manufacturer |
Hoffman-La Roche | |
Drug Type |
Immunotherapy | |
Delivery |
Intravenous | |
Approval Status |
Phase 3 | |
Indications |
||
Overall Strategy |
Immune system | |
Strategy |
Immunotherapy | |
Drug Category |
PD-L1 inhibitor |
The FDA has twice designated this drug as a breakthrough therapy.
An engineered anti PD-L1 antibody.
MPDL3280A (also known as anti-PDL1 and RG7446) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.